An update on medication management of behavioral disorders in autism (Q38184482)

30 August 2017

title

An update on medication management of behavioral disorders in autism (English)

1 reference

30 August 2017

0 references

Evdokia Anagnostou

1 reference

30 August 2017

Danielle A Baribeau

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 March 2014

1 reference

Current Psychiatry Reports

30 August 2017

published in

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

page(s)

437

1 reference

Use of psychotropic medication in children and adolescents with autism spectrum disorders

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Risperidone for autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Aripiprazole for autism spectrum disorders (ASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Aripiprazole in the Treatment of Irritability in Pediatric Patients (Aged 6–17 Years) with Autistic Disorder: Results from a 52-Week, Open-Label Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Model of autism: increased ratio of excitation/inhibition in key neural systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Glutamate mediated signaling in the pathophysiology of autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Decision making and antipsychotic medication treatment for youth with autism spectrum disorders: applying guidelines in the real world

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Urinary dopamine metabolites as indicators of the responsiveness to fenfluramine treatment in children with autistic behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Clinical and neurochemical effects of fenfluramine in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Examining autistic traits in children with ADHD: does the autism spectrum extend to ADHD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Use of methylphenidate in the treatment of children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Commentary: Filling out the evidence base for treatment of attention-deficit hyperactivity disorder symptoms in children with intellectual and developmental disability: conclusions for clinicians--a response to Simonoff et al. (2013).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish r

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Clonidine treatment of hyperactive and impulsive children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Guanfacine in children with autism and/or intellectual disabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Oxytocin increases retention of social cognition in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Promoting social behavior with oxytocin in high-functioning autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A randomised controlled trial of bumetanide in the treatment of autism in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A retrospective study of memantine in children and adolescents with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

The Clinical Global Impressions scale: errors in understanding and use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

The children's Yale-Brown obsessive-compulsive scale: psychometric properties of child- and parent-report formats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: psychometric properties and normative ratings from a school district sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

A teacher rating scale for use in drug studies with children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

The Nisonger CBRF: a child behavior rating form for children with developmental disabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-014-0437-0

Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity

21 January 2018

1 reference

12 December 2020

Assessment of tardive dyskinesia in psychiatric outpatients using a standardized rating scale

1 reference

12 December 2020

Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents

1 reference

12 December 2020

Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008

1 reference

12 December 2020

The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity

1 reference

12 December 2020

The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

1 reference

12 December 2020

How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis

1 reference

12 December 2020

10.1007/S11920-014-0437-0

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1046002411

0 references

1 reference